Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Nuclea Biotechnologies logo — company profile

Nuclea Biotechnologies

Founded 2005 United States Cambridge, United States 18 employees Venture round Total: $27.65M Biotechnology, Health Care

General Information

Company Name Nuclea Biotechnologies
Founded Year 2005
Location United States Cambridge, United States
Employees 18
Industries Biotechnology, Health Care
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with Nuclea Biotechnologies. To contact Nuclea Biotechnologies, visit nucleabio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Nuclea Biotechnologies compare?

A PDF of Nuclea Biotechnologies and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Nuclea Biotechnologies soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Nuclea Biotechnologies

Nuclea Biotechnologies is a biotechnology company founded in 2005 which is based in the United States. The company focuses on the development of IVD and RUO diagnostic assays and kits for the early detection and monitoring of biomarkers in oncology and endocrinology. Nuclea has made significant strides in this field, particularly with the acquisition of Oncogene Sciences ELISA products in 2013, including the HER2/neu IVD diagnostic kit, known as the gold standard in testing for metastatic breast cancer. Furthermore, Nuclea is a pioneer in mass spec testing and operates a CLIA lab in Cambridge, Massachusetts, offering a wide range of fully validated and reimbursable tests for proteins associated with cancer and chronic diseases. The company's focus on proteomic testing is particularly noteworthy, as it provides a personalized, real-time snapshot of disease due to the unique biomarkers in an individual's proteome. Nuclea has received a $1.07M Venture Round investment on 20 February 2013. This investment has contributed to the company's ongoing excellence and innovation in the rapidly growing biotechnology and healthcare industries. With its commitment to quality and advancement, Nuclea continues to set the standard for excellence in this field.

Funding Rounds & Investors (8)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round $1.07M -
20 Feb 2013
Series C $5.00M -
02 Aug 2012
Venture Round $555.00K -
03 May 2012
Venture Round $1.90M -
12 Apr 2012
Series B $3.40M -
02 Feb 2012
Series B $6.40M -
19 Aug 2011
Debt Financing $425.00K -
17 Dec 2010
Venture Round $8.90M -
10 Jun 2009

Nuclea Biotechnologies Alternatives & Competitors

View All Alternatives
Nuclea Biotechnologies vs
Geneseeq Technology Inc.
Geneseeq Technology Inc. Canada

Cancer: a word, not a sentence!

Series D
32 employees
Biotechnology, Health Care
Nuclea Biotechnologies vs
FIRALIS S.A.
FIRALIS S.A. France

Innovative biomarker solutions for improved diagnostics, enhancing patient outcomes and optimizing h...

Series B
28 employees
Biotechnology, Health Care
View all alternatives

FAQ About Nuclea Biotechnologies

Since our founding in 2005, Nuclea has been focused on the development of IVD and RUO diagnostic assays and kits for the early detection and monitoring of biomarkers in oncology and endocrinology. Our proprietary discovery platforms and clinical research network have resulted in a collection of nove...
Nuclea Biotechnologies was founded in 2005.
Nuclea Biotechnologies is headquartered in Cambridge, United States.
Nuclea Biotechnologies operates in Biotechnology and Health Care.
Nuclea Biotechnologies has approximately 18 employees.
Nuclea Biotechnologies has completed 8 funding rounds, raising a total of $27.65M. The latest funding stage is Venture round.
Top alternatives and competitors to Nuclea Biotechnologies include Geneseeq Technology Inc., FIRALIS S.A.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Nuclea Biotechnologies and Geneseeq Technology Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Nuclea Biotechnologies, https://bouncewatch.com/company/nuclea-biotechnologies, updated 27 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout